Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
2Debt Items
11Related Chains
Source-Backed Evidence Depth
Caris Life Sciences, Inc. (CAI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
8High confidence
0.804Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from GH graph: Reciprocal relationship from CAI graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was a…
Reciprocal relationship from PSNL graph: Reciprocal relationship from CAI graph: Reciprocal relationship from PSNL graph: t or potential competitors, including Adela, Inc., BostonGene Corporation, Ca…
Caris Life Sciences, Inc. Customers
Ticker
Name
Confidence
Evidence
BIOPHARMACEUTICAL-CUSTOMERS
BIOPHARMACEUTICAL-CUSTOMERS
90%
Pharma research and development services involving delivery of laboratory, strategic data, and research services to biopharmaceutical customers
INSTITUTIONS
INSTITUTIONS
90%
the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients
PATIENTS
PATIENTS
90%
the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients
COLLABORATIVE-PARTNERS
COLLABORATIVE-PARTNERS
85%
the Company recognizes revenue earned from the licenses of molecular data granted to the Company's collaborative partners
END-USERS
END-USERS
80%
the counterparty to these agreements meets the definition of a customer
Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in 2018; Caris Life Sciences, Inc.; Tempus AI, …
BRAIDWELL-TRANSACTION-HOLDINGS-LLC
BRAIDWELL-TRANSACTION-HOLDINGS-LLC
62%
ital expenditures, and our other GAAP results. The following table provides a reconciliation of net cash provided by (used in) operating activities, the most directly comparable financial measure pre…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
ital expenditures, and our other GAAP results. The following table provides a reconciliation of net cash provided by (used in) operating activities, the most directly comparable financial measure pre…
Caris Life Sciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CAI-DEBT
Debt stack $393.2M
90%
Market cache reports total debt of $393.2M.
CAI-DEBT-8452
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Caris Life Sciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Caris Life Sciences, Inc..
Caris Life Sciences, Inc. Ownership
Holder
Name
Confidence
Evidence
CAI-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 203 tracked holders.
Caris Life Sciences, Inc. Extended Supply Chain Network
